<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001984</url>
  </required_header>
  <id_info>
    <org_study_id>000013</org_study_id>
    <secondary_id>00-DK-0013</secondary_id>
    <nct_id>NCT00001984</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys</brief_title>
  <official_title>Tolerance Induction Following Human Renal Transplantation Using Treatment With a Humanized Monoclonal Antibody Against CD52 (Campath-1H)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will test a humanized monoclonal antibody known as Campath-1H for its ability
      to induce a state of permanent allograft acceptance, or tolerance, when administered in
      combination with a brief course of the immunosuppressive drug deoxyspergualin (DSG) at the
      time of human renal allotransplantation. Campath-1H is specific for the common lymphocyte and
      monocyte antigen CD52. Its administration temporarily depletes mature lymphocytes and some
      monocytes without altering neutrophils or hematopoietic stem cells. Deoxyspergualin inhibits
      the NFkB pathway thus preventing monocyte and macrophage activation.

      Recipients of living or cadaveric donor kidneys will be treated with one dose of Campath-1H
      prior to transplantation to insure that peripheral depletion is achieved at the time of graft
      reperfusion. Three subsequent doses of Campath-1H will be administered on the first, third
      and fifth days after the transplant to deplete passenger donor leukocytes and residual
      recipient cells that mobilize in response to the allograft. In addition, patients will be
      treated with DSG for 14 days beginning on the day prior to surgery. This trial expands on
      pilot studies at the NIH of 15 patients in which Campath was given alone at the time of
      transplantation. In those studies, excellent peripheral depletion occurred after just one
      dose of Campath though central depletion required additional dosing. This allowed for greatly
      reduced immunosuppression to be used to prevent rejection, but to date, all patients have
      required some immunosuppressive medication. It is hoped that the addition of DSG will
      eliminate the need for long-term immunosuppression.

      Patients will be followed closely in the post transplant period. If patients experience
      rejection, they will be treated with methylprednisolone and have immunosuppression added
      using sirolimus as the predominant immunosuppressive agent. In the previous phase of this
      study without DSG, this maneuver has in all cases been successful in returning the allograft
      to normal function.

      In addition to evaluating graft function following transplantation, this protocol will also
      characterize and evaluate the function of the immune system and the composition of the T cell
      repertoire following the administration of Campath-1H and DSG, and during immune system
      recovery after transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol will test a humanized monoclonal antibody known as Campath-1H for its ability
      to induce a state of permanent allograft acceptance, or tolerance, when administered in
      combination with a brief course of the immunosuppressive drug deoxyspergualin (DSG) at the
      time of human renal allotransplantation. Campath-1H is specific for the common lymphocyte and
      monocyte antigen CD52. Its administration temporarily depletes mature lymphocytes and some
      monocytes without altering neutrophils or hematopoietic stem cells. Deoxyspergualin inhibits
      the Rel-B/ NFkB pathway thus preventing monocyte and macrophage activation. Extensive
      preliminary data have been accumulated in humans using Campath-1H and its non-humanized
      predecessors. Additionally, data have been generated using a similar depleting scheme with
      and without DSG in non-human primates. Both the human and non-human primate data suggest that
      profound mature mononuclear cell depletion establishes a window of opportunity during which
      foreign tissue can be transplanted without the need for additional immunosuppression.
      Regulatory events occuring during mature cell repopulation in the presence of allografted
      tissue created a state in which the graft may not be rejected even in the absence of chronic
      immunosuppression.

      Recipients of living or cadaveric donor kidneys will be treated with one dose of Campath-1H
      prior to transplantation to insure that peripheral depletion is achieved at the time of graft
      reperfusion. Three subsequent doses of Campath-1H will be administered on the first, third
      and fifth days after the transplant to deplete passenger donor leukocytes and residual
      recipient cells that mobilize in response to the allograft. In addition, patients will be
      treated with DSG 4mg/kg/d x 1 beginning on day 12 and then 2.5 mg/kg/d for an additional 13
      days. This trial expands on pilot studies at the NIH of 17 patients in which Campath was
      dosed both prior to and after transplantation with and without DSG. In those studies,
      excellent peripheral depletion occured after just one dose of Campath though central
      depletion required additional dosing. Thus, the goal of pre-reperfusion depletion can be
      achieved with a single pre-operative dose but thorough depletion requires additional
      post-operative dosing. Lasting rejection-free survival was not realized without the addition
      of some, albeit reduced immunosuppression. This is thought to be due to residual
      post-operative monocytes that infiltrated the allograft causing modest reversible allograft
      dysfunction. The current dosing regimen with DSG is thus designed to accomplish both
      pre-operative depletion, and more thorough post operative elimination of donor and recipient
      cells mobilizing as a result of reperfusion, combined with therapy aimed at preventing the
      activation of monocytes that escape depletion. The timing of the DSG is meant to correspond
      with the peripheral repopulation of monocytes seen in previous patients.

      Patients will be followed closely in the post transplant period for evidence of a detrimental
      immune response to the allograft. In the previous patients experiencing graft directed
      immunity the graft dysfunction was preceded by a rise in activated monocytes in the
      peripheral blood and augmented transcription of the cytokine Tumor Necrosis Factor-alpha
      (TNF-a) in the allograft. This syndrome has been resistant to treatment with the TNF-a
      sequestrant Infliximab and is now thought to require more comprehensive monocyte directed
      therapy. If patients progress and graft dysfunction occurs, patients will be treated with
      methylprednisolone and have immunosuppression added using sirolimus as the predominant
      immunosuppressive agent. This maneuver has in all cases been successful in returning the
      allograft to normal function. Sirolimus has been chosen since it does not act by interfering
      with specific T cell receptor function, and thus, provides immunosuppressive coverage during
      cell repopulation without interfering with the antigen specific T cell events important for
      tolerance induction. Non-human primate and human clinical data support both of these
      approaches.

      In addition to evaluating graft and patient outcome following transplantation, this protocol
      will also characterize and evaluate the function of the immune system and the composition of
      the T cell repertoire following the administration of Campath-1H and DSG, and during immune
      system recovery after transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Renal Allograft Rejection</measure>
    <time_frame>from day 1 to 24 months post operation</time_frame>
    <description>The renal allograft tolerance was evaluated clinically, by flow cytometry, and by protocol biopsies analyzed immunohistochemically and with real-time polymerase chain reaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rejection Day of Onset</measure>
    <time_frame>From day 1 to 2 years post operation</time_frame>
    <description>The day on which the rejection onsets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rise in Serum Creatineine Above Posttransplant Nadir</measure>
    <time_frame>24-32 days post operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatinine Level at 6 Month Post Operation</measure>
    <time_frame>6 month post operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Level at Year 1 Post Operation</measure>
    <time_frame>1 year post operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine at 2 Years</measure>
    <time_frame>2 years post operation</time_frame>
    <description>Creatinine level of donor recepient at 2 years after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte Count</measure>
    <time_frame>4 day post operation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Graft Rejection</condition>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab and DSG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab and DSG</intervention_name>
    <description>Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.</description>
    <arm_group_label>Alemtuzumab and DSG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Candidates for a kidney transplant performed at the Warren G. Magnuson Clinical Center.

        Willingness and legal ability to give informed consent, or permission from a legal
        guardian.

        Willingness to travel to the Clinical Center for protocol specific samples to be taken, or
        in some cases, the ability to send samples via overnight mail.

        Availability of donor tissue for testing. This could include splenic or peripheral blood
        lymphocytes from a cadaveric donor or a willing living donor enrolled on the Clinic Center
        Living Donor Protocol who consents to periodic phlebotomy for peripheral blood lymphocyte
        isolation.

        EXCLUSION CRITERIA:

        Immunosuppressive drug therapy at the time of or 2 months prior to enrollment.
        Specifically, candidates must not be taking prednisone, cyclosporine, tacrolimus,
        azathioprine, mycophenolate mofetil, antilymphocyte agents, cyclophosphamide, methotrexate,
        or other agents whose therapeutic effect is immunosuppressive.

        Any condition that precludes serial follow-up.

        Any active malignancy or any history of a hematogenous malignancy or lymphoma. Patients
        with primary, cutaneous basal cell or squamous cell cancers may be enrolled providing the
        lesions are appropriately treated prior to transplant.

        Significant coagulopathy or requirement for anticoagulation therapy that would
        contraindicate protocol allograft biopsies.

        Platelet count less than 100,000/mm(3).

        Hemoglobin less than 9.0 mg/dl. Patients may be on erythropoietin therapy, but will not be
        placed on therapy solely to facilitate research sample acquisition.

        Any known immunodeficiency syndrome.

        HLA identical status with a living donor.

        Any history of uncompensated cardiac insufficiency, major vascular disease, or symptomatic
        coronary artery disease.

        Systemic or pulmonary edema.

        Inability to be effectively dialyzed.

        Chronic hypotension (SBP less than 100 mmHg).

        Any condition that would likely increase the risk of protocol participation or confound the
        interpretation of the data.

        CMV negative status receiving an organ from a known CMV positive donor.

        EBV negative status receiving an organ from a known EBV positive donor.

        Panel reactive antibody greater than 20% due to HLA antibodies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Santiago-Delp√≠n EA. Trends in kidney transplantation in the United States. Transplant Proc. 1998 Sep;30(6):2867-8.</citation>
    <PMID>9745602</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2000</study_first_posted>
  <results_first_submitted>September 13, 2010</results_first_submitted>
  <results_first_submitted_qc>September 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2010</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>Tolerance</keyword>
  <keyword>DSG</keyword>
  <keyword>Alemtuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Five patients aged 28-54 years scheduled to receive their first live-donor kidney transplant were enrolled after informed consent for study participation was obtained.</recruitment_details>
      <pre_assignment_details>Patients were excluded if they were: HLA identical with their donor; on immunosuppression within 6 months of enrollment; or medically unsuitable for transplantation. Cytomegalovirus negative recipients of cytomegalovirus positive grafts were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alemtuzumab and DSG</title>
          <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alemtuzumab and DSG</title>
          <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="28" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Relationship between Donor and Recepient</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Living related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Living unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of end-stage renal disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Membranous glomerulonephritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA nephropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polycystic kidney disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medullary cystic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obstructive uropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Renal Allograft Rejection</title>
        <description>The renal allograft tolerance was evaluated clinically, by flow cytometry, and by protocol biopsies analyzed immunohistochemically and with real-time polymerase chain reaction.</description>
        <time_frame>from day 1 to 24 months post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and DSG</title>
            <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Renal Allograft Rejection</title>
          <description>The renal allograft tolerance was evaluated clinically, by flow cytometry, and by protocol biopsies analyzed immunohistochemically and with real-time polymerase chain reaction.</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rejection Day of Onset</title>
        <description>The day on which the rejection onsets.</description>
        <time_frame>From day 1 to 2 years post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and DSG</title>
            <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Rejection Day of Onset</title>
          <description>The day on which the rejection onsets.</description>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="24" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Level at 6 Month Post Operation</title>
        <time_frame>6 month post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and DSG</title>
            <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Level at 6 Month Post Operation</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Level at Year 1 Post Operation</title>
        <time_frame>1 year post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and DSG</title>
            <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Level at Year 1 Post Operation</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine at 2 Years</title>
        <description>Creatinine level of donor recepient at 2 years after transplantation</description>
        <time_frame>2 years post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and DSG</title>
            <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine at 2 Years</title>
          <description>Creatinine level of donor recepient at 2 years after transplantation</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rise in Serum Creatineine Above Posttransplant Nadir</title>
        <time_frame>24-32 days post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and DSG</title>
            <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Rise in Serum Creatineine Above Posttransplant Nadir</title>
          <units>parcentage rise in serum creatineine</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="20" upper_limit="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocyte Count</title>
        <time_frame>4 day post operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and DSG</title>
            <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Monocyte Count</title>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527" lower_limit="370" upper_limit="1600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Alemtuzumab and DSG</title>
          <description>The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Allograft Rejection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>postbiopsy hemodynamically significant renal arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Grade II chronic allograft nepharopathy with proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Grade II CAN at year 1 post operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>OKT3 rescue requirement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alan Kirk</name_or_title>
      <organization>NIDDK, NIH</organization>
      <email>allank@intra.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

